Western Pacific Regional Green Light Committee: Progress and way forward

International Journal of Infectious Diseases

Volumn 32, Issue , 2015, Pages 161-165

  Islam, T ^a   Marais, B J ^b   Nhung, N V ^c   Chiang, C Y ^d   Yew, W W ^e   Yoshiyama, T ^f   Mira, N R ^g   van den Broek, J ^h   Lumb, R ⁱ   Nishikiori, N ^a   Reichman, L B ^j  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF SYDNEY   (Australia)

^c National TB Control Program   (Viet Nam)

^d Department of Lung Health and NCDs International Union Against Tuberculosis and Lung Disease ^*  (France)

^e Hong Kong Tuberculosis Chest and Heart Diseases Association   (Hong Kong)

^f RESEARCH INSTITUTE OF TUBERCULOSIS   (Japan)

^g UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^h KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

ⁱ Rundle Mall   (Australia)

^j RUTGERS UNIVERSITY   (United States)

more..

Author keywords

Drug resistant tuberculosis; PMDT; Programmatic management of drug resistant TB; RGLC; Western Pacific Regional Green Light Committee

Indexed keywords

ACHIEVEMENT; ARTICLE; AWARENESS; CAPACITY BUILDING; DRUG RESISTANT TUBERCULOSIS; HEALTH CARE ORGANIZATION; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; ORGANIZATION AND MANAGEMENT; ORGANIZATIONAL STRUCTURE; PROFESSIONAL STANDARD; SCALE UP; SYSTEM ANALYSIS; WESTERN PACIFIC REGIONAL GREEN LIGHT COMMITTEE; ADVISORY COMMITTEE; DISEASE MANAGEMENT; FORECASTING; TRENDS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADVISORY COMMITTEES; DISEASE MANAGEMENT; FORECASTING; HUMANS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84925234786     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2015.01.001     Document Type: Article

References (14)

1. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2006.361. Geneva, Switzerland: World Health Organization; 2006.
2. Meeting report of a ministerial meeting of high M/XDR-TB burden countries. WHO/HTM/TB/2009.415. Geneva, Switzerland: World Health Organization; 2009.
3. World Health Assembly. WHA 62.15. Prevention and control of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Sixty-second World Health Assembly, May 22, 2009, Geneva, Switzerland. Available at: (accessed October 10, 2014). http://apps.who.int/gb/ebwha/pdf_files/A62/A62_R15-en.pdf?ua=1.
4. The New Global Framework to support expansion of MDR-TB services and care [web page]. Geneva, Switzerland: World Health Organization. Available at: (accessed November 4, 2014). http://www.who.int/tb/challenges/mdr/greenlightcommittee/en/index.html.
5. Quelapio M.I., Mira N.R., Orillaza-Chi R.B., Belen V., Munez N., Belchez R., et al. Responding to the multidrug-resistant TB crisis: mainstreaming programmatic management to the Philippine National Tuberculosis Programme. Int J Tuberc Lung Dis 2010, 14:751-757.
6. Global tuberculosis report 2014. WHO/HTM/TB/2014.08 2014, World Health Organization, Geneva, Switzerland.
7. Islam T., Hiatt T., Hennig C., Nishikiori N. Drug-resistant tuberculosis in the WHO Western Pacific Region. Western Pac Surveill Response J 2014, 5. 10.5365/wpsar.2014.5.4.007.
8. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. WHO/HTM/TB/2013.6. Geneva, Switzerland: World Health Organization; 2013.
9. Islam T., van Weezenbeek C., Vianzon R., Garfin A.M., Hiatt T., Lew W.J., et al. Market size and sales pattern of tuberculosis drugs in the Philippines. Public Health Action 2013, 3:337-341.
10. Islam T, Quelapio M, van Weezenbeek C, Roa C, Vianzon L. Multidrug-resistant tuberculosis (MDR-TB) patients management in the private sector in the Philippines [Abstract]. Fourth Conference of The Union Asia-Pacific Region, International Union Against Tuberculosis and Lung Disease, April 10-13, 2013, Ha Noi, Viet Nam.
11. Zumla A. The Global Fund Round 11 cancellation fiasco: turning disaster into opportunity?. Int J Tuberc Lung Dis 2012, 16:285-286.
12. Chiang C.Y., Van Deun A., Enarson D.A. A poor drug-resistant tuberculosis programme is worse than no programme: time for a change. Int J Tuberc Lung Dis 2013, 17:714-718.
13. Lambregts-van Weezenbeek K.S., Reichman L.B. DOTS and DOTS-Plus: what's in a name. Int J Tuberc Lung Dis 2000, 4:995-996.
14. Global Drug-resistant TB Initiative [web page]. Geneva, Switzerland: World Health Organization. Available at: (accessed December 29, 2014). http://www.stoptb.org/wg/mdrtb/.